Edition:
United States

MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

4.57EUR
7 Dec 2016
Change (% chg)

€0.01 (+0.26%)
Prev Close
€4.56
Open
€4.57
Day's High
€4.62
Day's Low
€4.57
Volume
89,410
Avg. Vol
172,630
52-wk High
€5.00
52-wk Low
€2.80

Latest Key Developments (Source: Significant Developments)

MDxHealth raises 20.4 mln euros in equity placement
Thursday, 3 Nov 2016 08:00am EDT 

MDxHealth SA : MDxHealth successfully raises 20.4 million euros ($22.6 million) in equity placement .Payment and delivery of new shares is expected to take place on Nov. 7, 2016.  Full Article

Mdxhealth launches equity offering to raise of around 15 million euros
Wednesday, 2 Nov 2016 12:55pm EDT 

Mdxhealth Sa : Launched equity offering to raise an amount of approximately 15 million euros ($16.67 million) by means of a private placement of new shares . Says possibility to increase size of placement to up to 4,526,962 new shares in total (representing close to 10% of company's outstanding shares) .Bookbuilding procedure will commence immediately and is expected to close on Nov. 2, 2016, subject to acceleration or extension of timetable.  Full Article

Mdxhealth Q3 total revenues increased 122 pct to $9.1 million
Wednesday, 2 Nov 2016 12:46pm EDT 

MDxHealth SA : Q3 total revenues increased 122 pct to $9.1 million (Q3 2015: $4.1 million); up 45 pct from Q2 2016 ($6.3 million) . Q3 net loss declined 46 pct to $2.7 million (Q3 2015: $4.8million) .Maintains its upgraded guidance for projected 2016 revenues, which are expected to increase by more than 60 pct over 2015.  Full Article

MDxHealth signs agreement for distribution of SelectMDx in Poland
Wednesday, 19 Oct 2016 01:00am EDT 

MDxHealth SA :MDxHealth announces agreement with HIFU CLINIC prostate cancer center for distribution of SelectMDx in Poland.  Full Article

MDxHealth gets Medi-Cal Approval for ConfirmMDx
Tuesday, 6 Sep 2016 01:22am EDT 

Mdxhealth SA :Announced that ConfirmMDx for prostate cancer test is now available as an in-network benefit under California Medical Assistance Program (Medi-Cal).  Full Article

MDxHealth and Teva Pharmaceuticals sign distribution deal
Wednesday, 31 Aug 2016 01:06am EDT 

Mdxhealth SA : MDxHealth and Teva Pharmaceuticals sign distribution agreement for SelectMDx in Israel .Teva Pharmaceuticals will be exclusive distributor of selectMDx for prostate cancer test in Israel.  Full Article

Mdxhealth and Teva sign distribution agreement for selectMDX in Israel
Wednesday, 31 Aug 2016 01:05am EDT 

Mdxhealth SA :Mdxhealth and Teva pharmaceuticals sign distribution agreement for selectMDX in Israel.  Full Article

Mdxhealth H1 net loss widens to 7.6 million US dollars
Thursday, 18 Aug 2016 01:01am EDT 

MDxHealth SA : H1 revenue USD 13 million versus USD 7.9 million year ago . H1 EBITDA loss of USD 6.7 million versus loss of USD 5.3 million year ago . H1 net loss USD 7.6 million versus loss of USD 5.5 million year ago . Maintains its guidance for full year ending December 31, 2016 . 2016 guidance: revenue growth between 30 pct to 50 pct .Mark Shaffar appointed as chairman of the board.  Full Article

MDxHealth and Cerba Healthcare collaborate on SelectMDx commercialization
Monday, 25 Jul 2016 01:20am EDT 

MDxHealth SA : MDxhealth and Cerba Healthcare announce collaboration agreement for SelectMDx commercialization . Collaboration agreement to bring MDxHealth's SelectMDx for prostate cancer test to urology practitioners in France, Belgium and Luxembourg . Under the terms of this two-year agreement, Cerba Healthcare Belgium will offer the SelectMDx test through its laboratory network in France, Belgium and Luxembourg Further company coverage: [MDXH.BR] (Gdynia Newsroom:) ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;)).  Full Article

Mdxhealth secures new reimbursement coverage for SelectMdx
Tuesday, 28 Jun 2016 01:00am EDT 

Mdxhealth SA :Secures new reimbursement coverage for SelectMdx.  Full Article

BRIEF-Mdxhealth's AssureMDx multi-center validation study published in The Journal Of Urology

* Mdxhealth's AssureMDx multi-center validation study published in The Journal of Urology Source text for Eikon: Further company coverage: (Gdynia Newsroom)